Key clinical point: Compared with mastectomy, breast-conserving surgery (BCS) led to comparable locoregional recurrence (LRR; the first relapse site) events along with improved survival outcomes in patients with early-stage node-negative triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.
Major finding: BCS vs mastectomy following neoadjuvant chemotherapy did not increase LRR ( P = .5209) and was significantly associated with improved disease-free survival (adjusted hazard ratio [aHR] 0.51; P < .001) and overall survival (aHR 0.43; P < .001). Absence of pathologic complete response was the only determinant for worsened LRR risk (HR 2.22; P = .001).
Study details: This retrospective analysis of eight prospective trials included 1074 neoadjuvant chemotherapy-treated patients with early-stage node-negative TNBC and available surgery data.
Disclosures: This study received financial support from Deutschen Forschungsgemeinschaft (DFG) within the funding program Open Access Publikationskosten. Three authors declared being employees of GBG Forschungs GmbH. Ninel authors declared receiving honoraria, grants, consulting fees, or personal fees or having other ties with various sources. The other authors had no conflicts to declare.
Source: Krug D, Vladimirova V, Untch M, et al. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast. 2024;74:103701 (Feb 24). doi: 10.1016/j.breast.2024.103701 Source